SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-282259
Filing Date
2023-11-22
Accepted
2023-11-22 16:20:58
Documents
13
Period of Report
2023-11-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d797882d8k.htm   iXBRL 8-K 26589
2 EX-3.1 d797882dex31.htm EX-3.1 183901
  Complete submission text file 0001193125-23-282259.txt   376560

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20231116.xsd EX-101.SCH 2899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20231116_lab.xml EX-101.LAB 18724
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20231116_pre.xml EX-101.PRE 11737
7 EXTRACTED XBRL INSTANCE DOCUMENT d797882d8k_htm.xml XML 3567
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 231433763
SIC: 2836 Biological Products, (No Diagnostic Substances)